Honeybear Biosciences develops next‑generation radiopharmaceuticals and conjugated antibody therapeutics, focusing on Antibody‑Radionuclide Conjugates (ARCs) and Antibody‑Drug Conjugates (ADCs). Its lead radiopharmaceutical candidate, HB001, is in late‑stage preclinical development with an IND targeted by the end of 2026, and a second candidate, HB002, is expected to reach IND stage in 2027. The company operates a proprietary CoNectar® platform that enables site‑specific glycan conjugation and dual payload engineering, which Honeybear reports achieves process yields above 90% to improve product consistency and manufacturability. Honeybear states its preclinical candidates demonstrate favorable tumor accumulation, stability and promising safety profiles. It has expanded international collaborations with academic and industry partners—including Memorial Sloan Kettering Cancer Center, UCSF, PET Pharm Biotech, ASTAR and the Development Center for Biotechnology—as well as multiple CDMO partners to support clinical resources, radionuclide supply and manufacturing. Financially, Honeybear has raised $34 million in total capital following the recent $20 million Series A to accelerate global clinical development and licensing or partnership opportunities.

Total raised

$20M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2026